Mukka Proteins Intrinsic Value
MUKKA • Food Products
Current Stock Price
₹20.62
Primary Intrinsic Value
₹9.60
Market Cap
₹61.9 Cr
+100.0%
Upside
Median Value
₹41.24
Value Range
₹6 - ₹52
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
MUKKA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹9.60 | ₹7.68 - ₹11.52 | -53.4% | EPS: ₹0.80, Sector P/E: 12x |
| Book Value Method | asset | ₹51.55 | ₹46.39 - ₹56.70 | +150.0% | Book Value/Share: ₹152.33, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹41.24 | ₹37.12 - ₹45.36 | +100.0% | Revenue/Share: ₹322.67, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹41.24 | ₹37.12 - ₹45.36 | +100.0% | EBITDA: ₹72.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹22.64 | ₹18.11 - ₹27.17 | +9.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹6.19 | ₹5.57 - ₹6.81 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹6.59 | ₹5.93 - ₹7.25 | -68.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹41.24 | ₹37.12 - ₹45.36 | +100.0% | ROE: 6.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹52.36 | ₹47.12 - ₹57.60 | +153.9% | EPS: ₹0.80, BVPS: ₹152.33 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
MUKKA Intrinsic Value Analysis
What is the intrinsic value of MUKKA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Mukka Proteins (MUKKA) is ₹41.24 (median value). With the current market price of ₹20.62, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹6.19 to ₹52.36, indicating ₹6.19 - ₹52.36.
Is MUKKA undervalued or overvalued?
Based on our multi-method analysis, Mukka Proteins (MUKKA) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 102.89 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.90x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Mukka Proteins
Additional stock information and data for MUKKA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-112 Cr | ₹-130 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-150 Cr | ₹-174 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-56 Cr | ₹-58 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹2 Cr | ₹-5 Cr | Positive Operating Cash Flow | 6/10 |